| RS2135977542 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135977645 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2135977760 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2135978895 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2135979111 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2135979533 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2135984840 |
TRIM8
|
Health Risk |
Pathogenic/Likely pathogenic |
Seizure, Focal segmental glomerulosclerosis |
| RS2135984894 |
TRIM8
|
Health Risk |
Pathogenic |
Focal segmental glomerulosclerosis and neurodevelopmental syndrome, Focal segmental glomerulosclerosis and neurodevelopmental syndrome |
| RS2135984949 |
TRIM8
|
Health Risk |
Pathogenic/Likely pathogenic |
Focal segmental glomerulosclerosis and neurodevelopmental syndrome, Neurodevelopmental delay |
| RS2135984958 |
TRIM8
|
Health Risk |
Pathogenic |
Neurodevelopmental delay, Focal segmental glomerulosclerosis |
| RS2135985076 |
TRIM8
|
Health Risk |
Pathogenic/Likely pathogenic |
Focal segmental glomerulosclerosis and neurodevelopmental syndrome, Seizure |
| RS2135985089 |
TRIM8
|
Health Risk |
Pathogenic |
Focal segmental glomerulosclerosis and neurodevelopmental syndrome, Focal segmental glomerulosclerosis and neurodevelopmental syndrome |
| RS2135985150 |
TRIM8
|
Health Risk |
Pathogenic/Likely pathogenic |
Focal segmental glomerulosclerosis and neurodevelopmental syndrome, Seizure |
| RS2135990079 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2135990084 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2135990149 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2135990721 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2135990843 |
MYBPC1
|
Health Risk |
Likely pathogenic |
Abnormality of the musculature, Abnormality of the musculature |
| RS2135992770 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2135994295 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2135995131 |
PFKM
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type VII |
| RS2135995555 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Colorectal cancer, susceptibility to |
| RS2135997131 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2135997137 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2135999616 |
SLC17A8
|
Health Risk |
Pathogenic |
Autosomal dominant nonsyndromic hearing loss 25, Autosomal dominant nonsyndromic hearing loss 25 |
| RS2135999822 |
ITGA7
|
Health Risk |
Pathogenic |
Congenital muscular dystrophy due to integrin alpha-7 deficiency, Congenital muscular dystrophy due to integrin alpha-7 deficiency |
| RS2136000931 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136001004 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2136006298 |
TCTN1
|
Health Risk |
Likely pathogenic |
Joubert syndrome 13, Joubert syndrome 13 |
| RS2136007588 |
SYT1
|
Health Risk |
Pathogenic/Likely pathogenic |
Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome, Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome |
| RS2136007608 |
SYT1
|
Health Risk |
Pathogenic/Likely pathogenic |
Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome, Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome |
| RS2136008692 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136009658 |
PFKM
|
Health Risk |
Likely pathogenic |
— |
| RS2136010908 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2136011029 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2136011317 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2136011926 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136012123 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2136013780 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136013815 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2136015352 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2136015354 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2136015541 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Familial cancer of breast |
| RS2136015595 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2136016053 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2136016515 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2136017191 |
ATM
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2136017305 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Ataxia-telangiectasia syndrome |
| RS2136017422 |
ATM
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2136018060 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2136018731 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Ataxia-telangiectasia syndrome, Hereditary cancer-predisposing syndrome |
| RS2136018890 |
POLE
|
Health Risk |
Likely pathogenic |
— |
| RS2136019667 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2136020407 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2136020496 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Familial cancer of breast, Ataxia-telangiectasia syndrome |
| RS2136020791 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2136020836 |
SOX5
|
Health Risk |
Pathogenic |
— |
| RS2136025217 |
ITGA7
|
Health Risk |
Likely pathogenic |
Congenital muscular dystrophy due to integrin alpha-7 deficiency, Congenital muscular dystrophy due to integrin alpha-7 deficiency |
| RS2136027025 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2136027740 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136028810 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136029186 |
POLE
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2136029683 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136029710 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136029824 |
CHEK1
|
Health Risk |
Pathogenic |
Oocyte/zygote/embryo maturation arrest 21, Oocyte/zygote/embryo maturation arrest 21 |
| RS2136030901 |
UBE3B
|
Health Risk |
Pathogenic |
Oculocerebrofacial syndrome, Kaufman type |
| RS2136034222 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136034735 |
POLE
|
Health Risk |
Pathogenic |
— |
| RS2136044173 |
STAT2
|
Health Risk |
Pathogenic |
Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection, Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection |
| RS2136045792 |
TCTN1
|
Health Risk |
Likely pathogenic |
TCTN1-related disorder, TCTN1-related disorder |
| RS2136045991 |
ITGA7
|
Health Risk |
Likely pathogenic |
Congenital muscular dystrophy due to integrin alpha-7 deficiency, Congenital muscular dystrophy due to integrin alpha-7 deficiency |
| RS2136046122 |
SOX5
|
Health Risk |
Pathogenic |
Lamb-Shaffer syndrome, Lamb-Shaffer syndrome |
| RS2136047144 |
PHF21A
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures, Intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures |
| RS2136047948 |
SOX5
|
Health Risk |
Pathogenic |
See cases, Lamb-Shaffer syndrome |
| RS2136048818 |
FANCC
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2136049056 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2136049324 |
FANCC
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group C |
| RS2136049616 |
PCDH15
|
Health Risk |
Pathogenic/Likely pathogenic |
Autosomal recessive nonsyndromic hearing loss 23, Usher syndrome type 1D |
| RS2136049646 |
FANCC
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2136050284 |
ATP2B1
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder, autosomal dominant 66 |
| RS2136051965 |
POLE
|
Health Risk |
Pathogenic |
Facial dysmorphism-immunodeficiency-livedo-short stature syndrome, Facial dysmorphism-immunodeficiency-livedo-short stature syndrome |
| RS2136052256 |
STAT2
|
Health Risk |
Pathogenic |
Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection, Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection |
| RS2136052278 |
STAT2
|
Health Risk |
Likely pathogenic |
Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection, Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection |
| RS2136053029 |
STAT2
|
Health Risk |
Pathogenic |
Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection, Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection |
| RS2136056220 |
NDUFA12
|
Health Risk |
Pathogenic |
Mitochondrial complex I deficiency, nuclear type 23 |
| RS2136056222 |
ITGA7
|
Health Risk |
Pathogenic |
Congenital muscular dystrophy due to integrin alpha-7 deficiency, Congenital muscular dystrophy due to integrin alpha-7 deficiency |
| RS2136056550 |
NUP107
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 11 |
| RS2136060057 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2136061889 |
ATM
|
Health Risk |
Pathogenic/Likely pathogenic |
Ataxia-telangiectasia syndrome, Hereditary cancer-predisposing syndrome |
| RS2136063413 |
UBE3B
|
Health Risk |
Pathogenic |
Oculocerebrofacial syndrome, Kaufman type |
| RS2136066523 |
UBE3B
|
Health Risk |
Pathogenic |
Oculocerebrofacial syndrome, Kaufman type |
| RS2136067033 |
UBE3B
|
Health Risk |
Pathogenic |
Oculocerebrofacial syndrome, Kaufman type |
| RS2136069811 |
NDUFA12
|
Health Risk |
Pathogenic |
Mitochondrial complex I deficiency, nuclear type 23 |
| RS2136072590 |
ITGA7
|
Health Risk |
Likely pathogenic |
Congenital muscular dystrophy due to integrin alpha-7 deficiency, Congenital muscular dystrophy due to integrin alpha-7 deficiency |
| RS2136073462 |
ITGA7
|
Health Risk |
Pathogenic/Likely pathogenic |
Congenital muscular dystrophy due to integrin alpha-7 deficiency, Congenital muscular dystrophy due to integrin alpha-7 deficiency |
| RS2136074154 |
PEX5
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 2B, Peroxisome biogenesis disorder 2B |
| RS2136075415 |
PEX5
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 2B, Peroxisome biogenesis disorder 2B |
| RS2136075449 |
NDUFA12
|
Health Risk |
Pathogenic |
— |
| RS2136075793 |
SOX5
|
Health Risk |
Pathogenic |
Lamb-Shaffer syndrome, Lamb-Shaffer syndrome |
| RS2136077497 |
COL13A1
|
Health Risk |
Pathogenic |
Congenital myasthenic syndrome 19, Congenital myasthenic syndrome 19 |